| Effect | None |
| Trial Design | Double blind |
| Trial Length | 6+ Months |
| Number of Subjects | 30 |
| Sex | Both Genders |
| Age Range | 45-64 |
| Body Types | Overweight |
In type II diabetics with an HbA1c over 8.5% given 1mg of chromium via yeast, supplementation was associated with a reduction in blood glucose (11%) and HbA1c (0.7%, from 10.2% to 9.5%) alongside an increase in insulin sensitivity.
Lipid peroxidation, as assessed by TBARS, was also reduced with chromium by 18.7%. An increase in glutathoine peroxidase was noted, but catalase and SOD were unaffected.
